^
Association details:
| Biomarker: | EGFR negative |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + Tyvyt (sintilimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II Clinical Trail of Anlotinib Combined with Sintilimab in the Second-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer.
Excerpt:
...Provide detectable specimens (tissue or pleural effusion specimens) for PD-L1 expression detection and genotype testing*, patients with negative EGFR-sensitive mutations, ALK fusion, and ROS1 fusion gene test would be enrolled; or patients with positive test results but who have received relevant targeted drug treatment and have progressed. ...
Trial ID:
Source:
Title:
166P - First-line anlotinib-based combination treatment for patients with advanced non-small cell lung cancer: A three arms, prospective study
Published date:
03/17/2021
Excerpt:
In this open-label, three arm, prospective study, advanced NSCLC patients...with EGFR mutation negative, the treatment regimen was anlotinib in combination with chemotherapy (Cohort B) or sintilimab (Cohort C) according to investigator…. In Cohort C, medium PFS was 15.6 months. The 18- and 24-month PFS rate was 45.9% and 26.2%, respectively....For EGFR-mutated negative patients, anlotinib combines with chemotherapy or sintilimab also may be a promising first-line treatment.
Trial ID:
